Phenibut

Evidence tier D. International alcohol withdrawal guidelines (ASAM 2020, NICE CG100) list benzodiazepines (diazepam, lorazepam, chlordiazepoxide) as first-line therapy, with phenobarbital and gabapentin as alternatives in specific scenarios. Phenibut is proposed in some Russian addiction protocols based on its GABA-B activity but lacks methodologically strong RCTs outside Russia. Adding phenibut to a benzodiazepine taper in a polydependent patient increases the risk of mixed dependence and complicated withdrawal.

ICD-10: F10.3 · ICD-11: 6C40.4

Phenibut (β-phenyl-γ-aminobutyric acid) is a Soviet anxiolytic with GABA-B agonist activity. In Russia it is prescribed for anxiety, sleep disturbances, and asthenia. In biohacker communities, phenibut is promoted as a nootropic for cognitive enhancement in healthy adults. The drug is not approved by the FDA, EMA, or AEMPS and is not included in any international clinical guidelines. In 2019 the US FDA issued warning letters stating that phenibut does not meet the definition of a dietary ingredient and that products containing it are misbranded; US poison-center calls rose over the same period. The drug has serious risks: rapid development of dependence (even after several weeks of regular use), severe withdrawal syndrome (anxiety, insomnia, tachycardia, psychosis, sometimes seizures, may require hospital treatment), coordination disturbances, and sedation. If phenibut is being taken for anti-aging, concentration, or anxiety, consider seeking a second opinion; safer evidence-based alternatives exist.

Evidence tier D. Phenibut is not included in international anxiety guidelines (NICE CG113). Small Soviet-era and Russian RCTs report anxiolytic effects, but methodological quality (sample size, blinding, outcome measurement, follow-up) does not meet contemporary standards. A separate and growing concern: case series in Australia, New Zealand and the United States document dependence, severe withdrawal syndromes with delirium and rebound anxiety, and overdose with respiratory depression in users who acquire phenibut through online grey markets. First-line evidence-based therapy for GAD is cognitive behavioural therapy plus an SSRI or SNRI, with pregabalin and buspirone as second-line.

ICD-10: F41.1 · ICD-11: 6B00

Evidence tier F. International insomnia guidelines (AASM 2017, AASM 2021, European Sleep Research Society 2023) do not include phenibut. First-line therapy for chronic insomnia is cognitive behavioural therapy for insomnia (CBT-I). Pharmacological options when CBT-I is unavailable or insufficient include low-dose doxepin, melatonin receptor agonists and short-term use of "Z-drugs" or benzodiazepines, all in time-limited regimens. Chronic phenibut use for insomnia is particularly hazardous because tolerance develops within weeks and withdrawal itself causes severe rebound insomnia, anxiety and autonomic instability.

ICD-10: G47.0 · ICD-11: 7A00

Evidence tier F. International guidelines for panic disorder (NICE CG113) recommend cognitive behavioural therapy and SSRIs (sertraline, paroxetine, escitalopram) or SNRIs (venlafaxine) as first-line treatment. Benzodiazepines are reserved for short-term use. Phenibut has not been studied in panic disorder in indexed international literature and is not recommended in this role. Off-label phenibut use in panic disorder carries documented risk of dependence and severe withdrawal.

ICD-10: F41.0 · ICD-11: 6B01